The DOI matches its Crossref record.
Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators
Abstract
Summary This report updates the combined experience of four centres involved in the long‐term treatment of transfusional iron overload in 84 patients with the oral iron chelator deferiprone (L1) over 167 patient‐years. The source of L1 was variable, including two university research laboratories and three pharmaceutical firms. Compliance was rated as excellent in 48%, intermediate in 36%, and poor in 16% of patients. On a mean L1 dose of 73–81 mg/kg/d, urinary iron excretion was stable, at around 0 5 mg/kg/d, with no indication of a diminishing response with time. Serum ferritin showed a very steady decrease with time from an initial mean ±1SD of 4207 ±3118 to 1779 ± 1154μg/1 after 48 months (P< 0–001). 17 patients abandoned L1 therapy, Major complications of L1 requiring permanent discontinuation of treatment included agranulocytosis (three), severe nausea (four), arthritis (two) and persistent liver dysfunction (one). The remaining patients abandoned treatment because of low compliance (three) and conditions unrelated to L1 toxicity (four). Lesser complications permitting continued L1 treatment included transient mild neutropenia (four), zinc deficiency (12), transient increase in liver enzymes (37), moderate nausea (three) and arthropathy (17). There was no treatment‐related mortality. Although the complications associated with L1 treatment are significant and require close monitoring, they do not preclude effective long‐term therapy in the vast majority of patients. Further well‐controlled prospective studies of L1 are required in order to enable proper judgement of its suitability for general long‐term clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
Self-citationLong-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major
Olivieri, N. F., Brittenham, G. M., McLaren, C. E., Templeton, D. M., Cameron, R. G., McClelland, R. A., Burt, A. D., & Fleming, K. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390701 · Cited by 420
Self-citationPractical management of iron overload
Porter, J. B. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03195.x · Cited by 378
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone
Cohen, A. R., Galanello, R., Piga, A., De Sanctis, V., & Tricta, F. (2003) · Blood · doi:10.1182/blood-2002-10-3280 · Cited by 323
Steinberg, M. H. (2008) · The Scientific World JOURNAL · doi:10.1100/tsw.2008.157 · Cited by 293
Metadata
- Authors
- Al‐Refaie, F. N., Hershko, C., Hoffbrand, A. V., Kosaryan, M., Olivieri, N. F., Tondury, P., & Wonke, B.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 1995-09
- Volume
- 91
- Issue
- 1
- Pages
- 224-229
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2132319098
- Cited by
- 164
- References
- 0
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. https://app.cochat.ai/papers/10.1111/j.1365-2141.1995.tb05274.x
- The paper
- Al‐Refaie, F. N., Hershko, C., Hoffbrand, A. V., Kosaryan, M., Olivieri, N. F., Tondury, P., & Wonke, B. (1995). Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.1995.tb05274.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.